The vaccine targets alpha-lactalbumin, also known as α-lactalbumin, a milk protein. It is sometimes referred to as a “retired protein” because it is not typically found in non lactating people’s tissues. However, it does occur in the majority of TNBC cases.
The vaccine, also known as the aLA breast cancer vaccine, is expected to work similar to vaccines used to treat infectious diseases. In other words, it will stimulate the body’s immune system to eliminate this cancer.
The goal is to train the immune system to eliminate α-lactalbumin-expressing cells. This, in theory, will prevent tumor’s from forming.
Researchers hope to determine the maximum tolerable dose in the current phase 1 trial. Participants will receive three vaccinations, each in a different dose, two weeks apart.